OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development
Opko Health, Inc. (OPK)
Last opko health, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.opko.com
Company Research
Source: GlobeNewswire
WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. “Dr. Abbadessa’s deep experience in leading early-stage oncology development makes him the ideal fit to steer development of our multispecific antibodies for cancer and other clinical indications,” said Dr. Gary Nabel, co-founder, President and CEO of ModeX Therapeutics. “Dr. Abbadessa has invaluable expertise at every clinical phase and I’m confident he will facilitate a united and collaborative process as our portfolio grows.” Dr. Abbadessa is an entrepreneurial oncology developer with advanced technical and leadership experience. He has brought a
Show less
Read more
Impact Snapshot
Event Time:
OPK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPK alerts
High impacting Opko Health, Inc. news events
Weekly update
A roundup of the hottest topics
OPK
News
- OPKO Health, Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.MarketBeat
- Greenberg Traurig Advises OPKO Health in $237.5 Million Asset Sale to LabcorpPR Web
- OPKO Health, Inc. (NASDAQ: OPK) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $2.25 price target on the stock.MarketBeat
- Labcorp Stock Gains From Its Latest Acquisition of BioReference Health [Yahoo! Finance]Yahoo! Finance
- OPKO Health, Inc. (NASDAQ: OPK) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $3.00 price target on the stock.MarketBeat
OPK
Earnings
- 8/7/24 - Beat
OPK
Sec Filings
- 9/27/24 - Form 4
- 9/27/24 - Form 4/A
- 9/26/24 - Form 4
- OPK's page on the SEC website